Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DMAC

DMAC - DiaMedica Therapeutics Inc Stock Price, Fair Value and News

$8.45-0.31 (-3.54%)
Market Closed

Price Targets

DMAC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DMAC Price Action

Last 7 days

6.0%

Last 30 days

2.1%

Last 90 days

20.7%

Trailing 12 Months

42.0%

DMAC RSI Chart

DMAC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DMAC Valuation

Market Cap

440.1M

Price/Earnings (Trailing)

-13.78

Price/Sales (Trailing)

1.6K

EV/EBITDA

-13.71

Price/Free Cashflow

-15.84

DMAC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

DMAC Fundamentals

DMAC Revenue

Revenue (TTM)

205.0K

DMAC Earnings

Earnings (TTM)

-31.9M

Earnings Growth (Yr)

-37.39%

Earnings Growth (Qtr)

-11.96%

DMAC Profitability

EBT Margin

-15560.49%

Return on Equity

-61.85%

Return on Assets

-55.96%

Free Cashflow Yield

-6.31%

DMAC Investor Care

Shares Dilution (1Y)

21.79%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2020797.0K636.0K398.0K205.0K
2019589.0K678.0K767.0K856.0K
2018000500.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About DiaMedica Therapeutics Inc

DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
 CEO
 WEBSITEdiamedica.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16

DiaMedica Therapeutics Inc Frequently Asked Questions

DMAC is the stock ticker symbol of DiaMedica Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of DiaMedica Therapeutics Inc is 440.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DMAC's fair value in chart for subscribers.

The fair value guage provides a quick view whether DMAC is over valued or under valued. Whether DiaMedica Therapeutics Inc is cheap or expensive depends on the assumptions which impact DiaMedica Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DMAC.

As of Wed Jan 28 2026, DMAC's PE ratio (Price to Earnings) is -13.78 and Price to Sales (PS) ratio is 1.6 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DMAC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, DiaMedica Therapeutics Inc has provided 0.145 (multiply by 100 for percentage) rate of return.